Major Ingredients

Each film coated tablet contains Erdafitinib INN 5.00 mg.

Major Functionality

It is indicated for the treatment of adult patients with locally advanced or metastatic Urothelial Carcinoma (mUC), that has- · Susceptible FGFR3 or FGFR2 genetic alterations, and · Progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

Manufacture Information

Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.